Compare Charles Schwab Corporation Common Stock (SCHW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Charles Schwab Corporation Common Stock trades at $96.91 (market cap $167.52B), while State Street SPDR S&P Biotech ETF trades at $153.87 (market cap $10.11B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 16.6× State Street SPDR S&P Biotech ETF's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles Schwab Corporation Common Stock for 85 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SCHW | XBI | |
|---|---|---|
Market Cap | $167.52B | $10.11B |
Volume | 6,554,126 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $113.65 | $169.55 |
52-Week Low | $85.35 | $104.99 |
Typical Hold Time | 85 Days | 38 Days |
Enterprise Value | $153.97B | — |
Dividend Yield | 1.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $96.80, up 1.28% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 17.64, net income margin of 38.79%, and robust cash flow. Recent news highlights growth in client assets to $13.41 trillion and a strategic AI partnership with Anthropic.
The outlook is positive with a consensus price target of $120.33, implying significant upside. Risks include competitive pressures and market volatility, but strong earnings momentum and a favorable industry growth forecast support a bullish case for long-term investors.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
